

ABSTRACT

Interleukin-4 (IL-4) utilizes a specific IL-4 receptor chain with the common γ chain for transmembrane signaling. The present invention relates to hIL-4 muteins that demonstrate reduced affinity and altered specificity to the common γ chain. These muteins have therapeutic potential as IL-4 antagonists.

TECH CENTER 1800/2000